Evidence map›Paper›PMID 32749642›Full record

ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2020

Impact of Corona Virus Disease-19 (COVID-19) pandemic on gastrointestinal disorders.

Amol Nanak Singh Baryah, Vandana Midha, Ramit Mahajan, Ajit Sood

Open access · bronzeAbstract readReview
In one paragraph

Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Post-infection irritable bowel syndrome following Coronavirus disease-19: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Corona Virus Disease-19 pandemic: The gastroenterologists' perspective.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020
    Review
  9. SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amol Nanak Singh BaryahDepartment of Medicine, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
Vandana MidhaDepartment of Medicine, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
Ramit MahajanDepartment of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.
Ajit SoodDepartment of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India. ajitsood10@gmail.com.ORCID 0000-0001-6961-6389
Dayanand Medical College & Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worldwide, several hospitals in different regions and countries have been affected with Corona Virus Disease-19 (COVID-19). All medical specialties including gastroenterology are impacted by COVID-19. Here, we review the bidirectional comorbidity of chronic gastrointestinal (GI) disorders and COVID-19, including the incidence and outcome of COVID-19 in individuals with various GI disorders and the impact of COVID-19 on the course and outcome of the underlying (or comorbid) GI disorders. Currently, there is no evidence that COVID-19 is more (or less) frequent in comorbid GI disorders. It is also reassuring that the outcome of COVID-19 is unaffected by the underlying GI disorder or its treatment, though potential concerns remain in regard to the use of immunomodulatory treatments in inflammatory bowel disease (IBD) and liver transplant recipients. Despite these concerns, there is now agreement among experts that ongoing immunomodulatory treatments may not be interrupted in individuals with IBD during the COVID-19 pandemic. Caution, however, may be exercised with the use of corticosteroids in the management of IBD. In addition, COVID-19 does not appear to impact the manifestations, course, outcome, and treatment of comorbid GI disorders, e.g. IBD. Decompensation of liver cirrhosis is, however, possible during COVID-19 episodes. A direct concern, however, might relate to the potential transmission of the virus through fecal microbiota transplants.

Indexed as

Coronavirus InfectionsGastrointestinal DiseasesImmunomodulationPandemicsPneumonia, ViralBetacoronavirusComorbidityCOVID-19HumansSARS-CoV-2ComorbidityCorona VirusCOVID-19Crohn diseaseDiarrheaImmunosupressionInflammatory bowel diseasePandemicUlcerative colitis

Identifiers

PMID32749642
PMCPMC7399026
OpenAlexW3047221650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.